Madrigal Pharmaceuticals, Inc. (MDGL)
- Previous Close
233.36 - Open
234.32 - Bid 232.16 x 100
- Ask 234.12 x 100
- Day's Range
230.94 - 239.53 - 52 Week Range
119.76 - 299.98 - Volume
150,949 - Avg. Volume
282,791 - Market Cap (intraday)
5.063B - Beta (5Y Monthly) -0.44
- PE Ratio (TTM)
-- - EPS (TTM)
-25.55 - Earnings Date Nov 4, 2024 - Nov 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
362.53
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
www.madrigalpharma.comRecent News: MDGL
View MorePerformance Overview: MDGL
Trailing total returns as of 9/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MDGL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MDGL
View MoreValuation Measures
Market Cap
5.07B
Enterprise Value
4.13B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
317.47
Price/Book (mrq)
5.91
Enterprise Value/Revenue
281.95
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-47.27%
Return on Equity (ttm)
-106.27%
Revenue (ttm)
14.64M
Net Income Avi to Common (ttm)
-510.45M
Diluted EPS (ttm)
-25.55
Balance Sheet and Cash Flow
Total Cash (mrq)
1.06B
Total Debt/Equity (mrq)
13.77%
Levered Free Cash Flow (ttm)
-278.01M